News

High-profile infanticide trial fuels debate over postpartum illness, malpractice claims, and whether psychiatrists should be judged for patients’ crimes rather than care quality.

Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.

Impaired self-awareness is a frequent and impactful consequence of traumatic brain injury (TBI), occurring in as many as 40% to 80% of individuals with moderate-to-severe TBI. Deficits in self-awareness can negatively impact goal setting, treatment compliance, and motivation for therapy. Addressing this impairment through targeted interventions can improve rehabilitation outcomes, psychosocial adjustment, and community participation.

Bipolar depression does not have a single face. Through one patient’s journey, this case-based reflection explores 5 distinct presentations and how each can shape clinical recognition and treatment.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

How online scams and AI deepfakes prey on people with schizophrenia, triggering relapse—plus practical clinician screening and safety planning tips.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

A psychotherapist recommends standout books that help artists face doubt, master practice, and protect vision—insightful guidance across mediums.

See the latest in this psychiatric news roundup.

FDA clears a simple pTau217 blood test that helps clinicians rule in or out Alzheimer’s amyloid earlier, expanding access beyond PET/CSF.

In this CME article, explore why migraine often coexists with depression and anxiety, and get practical tips for diagnosis, prevention, and smarter prescribing.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.

FDA acceptance of mitragynine IND launches NIH phase 1 trial for opioid use disorder, tracking safety, dosing, and PK amid new DEA scheduling moves.

Digital reading boosts convenience but weakens comprehension and memory; evidence links “digital amnesia” to shallower learning, making print vital for deep clinical study.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

FDA signals clear IND path for PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

FDA clears a Parkinson disease wearable and fast-tracks ecopipam for pediatric Tourette syndrome, showing advances in neuropsychiatric care.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

Remote, home-based tDCS shows modest symptom relief and higher remission in major depression, with generally good safety but burn risks to watch.

A quick recap of the last week in psychiatric news.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

"...time slowed to the tide’s rhythm and the surf’s roar, each day closed by a Great Horned Owl’s silent fly-by at dusk..."

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Why modern psychiatry risks missing the person: It's time to revive biopsychosocial, cultural, and spiritual history beyond DSM checklists and EHR bloat.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.